ReviewJournal of hematology & oncology2010
Targeted therapy in lymphoma.
Review in Journal of hematology & oncology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 26 citations in OpenAlex.
- Construction methods and latest applications of kidney cancer organoids.Oncology reviews · 2024Review
- mTOR activity in AIDS-related diffuse large B-cell lymphoma.PloS one · 2017Article
- Pharmacological targeting of valosin containing protein (VCP) induces DNA damage and selectively kills canine lymphoma cells.BMC cancer · 2015Article
- Nanoparticle Formulations of siRNA: The Next Generation of Targeted Therapy for Lymphomas and Leukemias?EBioMedicine · 2014Article
- T cell immune abnormalities in immune thrombocytopenia.Journal of hematology & oncology · 2014Review
- Combination of BCL11A siRNA with vincristine increases the apoptosis of SUDHL6 cells.European journal of medical research · 2014Article
- MicroRNA-100/99a, deregulated in acute lymphoblastic leukaemia, suppress proliferation and promote apoptosis by regulating the FKBP51 and IGF1R/mTOR signalling pathways.British journal of cancer · 2013Article
- Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma.Journal of hematology & oncology · 2013Article
- Blockade of PI3K/AKT pathway enhances sensitivity of Raji cells to chemotherapy through down-regulation of HSP70.Cancer cell international · 2013Article
- Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model.Cellular & molecular immunology · 2012Article
- Novel CD20 monoclonal antibodies for lymphoma therapy.Journal of hematology & oncology · 2012Review
- Rituximab and new regimens for indolent lymphoma: a brief update from 2012 ASCO Annual Meeting.Cancer cell international · 2012Article
- Effect of phenylhexyl isothiocyanate on aberrant histone H3 methylation in primary human acute leukemia.Journal of hematology & oncology · 2012Article
- The Role of mTOR Inhibitors for the Treatment of B-Cell Lymphomas.Advances in hematology · 2012Article
- High nuclear expression of STAT3 is associated with unfavorable prognosis in diffuse large B-cell lymphoma.Journal of hematology & oncology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Discovery of new treatments for lymphoma that prolong survival and are less toxic than currently available agents represents an urgent unmet need. We now have a better understanding of the molecular pathogenesis of lymphoma, such as aberrant signal transduction pathways, which have led to the discovery and development of targeted therapeutics. The ubiquitin-proteasome and the Akt/mammalian target of rapamycin (mTOR) pathways are examples of pathological mechanisms that are being targeted in drug development efforts. Bortezomib (a small molecule protease inhibitor) and the mTOR inhibitors temsirolimus, everolimus, and ridaforolimus are some of the targeted therapies currently being studied in the treatment of aggressive, relapsed/refractory lymphoma. This review will discuss the rationale for and summarize the reported findings of initial and ongoing investigations of mTOR inhibitors and other small molecule targeted therapies in the treatment of lymphoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.